Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis): Fatal or nonfatal stroke
Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Angiotensin receptor blockers vs angiotensin‐converting‐enzyme inhibitors Fatal or nonfatal stroke Median · people with diabetes and kidney disease Angiotensin receptor blockers showed no clear difference in fatal or nonfatal stroke Median compared with angiotensin‐converting‐enzyme inhibitors (low certainty). Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of… (2024) · Cochrane Headline outcomes only | RR 0.92 [0.38, 2.24] | 5 studies · 1146 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Angiotensin‐converting‐enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease 2024 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.